Elecoglipron Compared With Placebo in Adults With Certain Types of Heart Failure
Tests elecoglipron against placebo for heart outcomes in adults with HFpEF or HFmrEF.
Plain-language title generated from the registry record
Registry title: A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
Key facts
- Where
- Bad Oldesloe, Bamberg, Berlin, Bielefeld, Bremen, Chemnitz, Cologne, Dresden, Elsterwerda, Erlangen, Essen, Freiburg im Breisgau, Gera, Hamburg, Heidelberg, Homburg, Jena, Kaiserslautern, Karlsbad, Kiel, Ludwigshafen, Ludwigshafen Am Rhein, Lüneburg, Magdeburg, Mainz, Markkleeberg, Mühldorf am Inn, Neuruppin, Nürnberg, Obertshausen, Paderborn, Papenburg, Stuttgart, Trier, Tuebingen, and Ulm, GermanySee the 42 sites
- Phase
- Phase 3
Where in Germany
- Asklepios Klinik Gauting GmbHBad Oldesloe, GermanyTaking people
- CIMS Studienzentrum Bamberg GmbHBamberg, GermanyTaking people
- Caritas Gesundheit Berlin gGmbHBerlin, GermanyTaking people
- Kardiologische Praxis KARDIABerlin, GermanyTaking people
- Vivantes Netzwerk fuer Gesundheit GmbHBerlin, GermanyTaking people
- Klinikum Bielefeld gGmbHBielefeld, GermanyTaking people
- Cardio Consult GbRBremen, GermanyTaking people
- Klinikum Chemnitz gGmbHChemnitz, GermanyTaking people
- St. Vinzenz-Hospital GmbHCologne, GermanyTaking people
- Herzzentrum Dresden GmbH UniversitaetsklinikDresden, GermanyTaking people
- Zentrum fuer klinische Studien Suedbrandenburg GmbHElsterwerda, GermanyTaking people
- Universitaetsklinikum Erlangen AöRErlangen, GermanyTaking people
- Universitaetsklinikum Essen (AoR)Essen, GermanyTaking people
- Medical Center- University of FreiburgFreiburg im Breisgau, GermanyTaking people
- SRH Wald-Klinikum Gera GmbHGera, GermanyTaking people
- Asklepios Klinik St GeorgeHamburg, GermanyTaking people
- Asklepios Kliniken Hamburg GmbHHamburg, GermanyTaking people
- Asklepios Westklinikum Hamburg GmbHHamburg, GermanyTaking people
- Kardiologie am Tibarg - StudiengesellschaftHamburg, GermanyTaking people
- Universitaetsklinikum Heidelberg AöRHeidelberg, GermanyTaking people
- Universitaetsklinikum des Saarlandes AöRHomburg, GermanyTaking people
- Universitaetsklinikum Jena KöRJena, GermanyTaking people
- Kardiopraxis SchirmerKaiserslautern, GermanyTaking people
- SRH Klinikum Karlsbad-Langensteinbach GmbHKarlsbad, GermanyTaking people
- Universitaetsklinikum Schleswig-Holstein AöRKiel, GermanyTaking people
- Kardiologische Praxisklinik LudwigshafenLudwigshafen, GermanyTaking people
- Klinikum der Stadt Ludwigshafen am Rhein gGmbHLudwigshafen Am Rhein, GermanyTaking people
- Praxis OedemeLüneburg, GermanyTaking people
- Universitaetsklinikum Magdeburg AöRMagdeburg, GermanyTaking people
- CardioScienceMainz, GermanyTaking people
- Marienhaus Klinikum Mainz GmbHMainz, GermanyTaking people
- Praxis Dr. Jens TaggeselleMarkkleeberg, GermanyTaking people
- herznah GemeinschaftspraxisMühldorf am Inn, GermanyTaking people
- Ruppiner Kliniken GmbHNeuruppin, GermanyTaking people
- Kardiologische Gemeinschaftpraxis Dr. med. Haggenmiller/Prof. Dr. med. JeserichNürnberg, GermanyTaking people
- Rahman & Detho Studien GmbHObertshausen, GermanyTaking people
- St. Vincenz-Krankenhaus GmbHPaderborn, GermanyTaking people
- Dr. med. Andreas Wilke Dr. med. Andrej Malazhavy und Detelin Lalev Denchev Fachaerzte Innere Medizin und Kardiologie PartnerschaftPapenburg, GermanyTaking people
- Vinzenz Von Paul Kliniken gGmbHStuttgart, GermanyTaking people
- Barmherzige Brueder Trier gGmbHTrier, GermanyTaking people
- Universitaetsklinikum Tuebingen AöRTuebingen, GermanyTaking people
- Cardiologicum Herzklinik Ulm MVZ GmbHUlm, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07761117EU 2026-526304-79-00
- Record updated
- 28 September 2026
- Original description
This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to investigate CV outcomes with elecoglipron compared with placebo, in adults with heart failure with preserved ejection fraction (HFpEF)/heart failure with mildly reduced ejection fraction (HFmrEF), irrespective of T2DM status, and who are on background dapagliflozin in addition to other background standard of care.Read full original descriptionShow less
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants With HFpEF and HFmrEF (Elevate-HF)
This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to investigate CV outcomes with elecoglipron compared with placebo, in adults with heart failure with preserved ejection fraction (HFpEF)/heart failure with mildly reduced ejection fraction (HFmrEF), irrespective of T2DM status, and who are on background dapagliflozin in addition to other background standard of care.
Inclusion: Left ventricular ejection fraction (LVEF) of > 40% within 12 months prior to screening; Structural heart disease evidence; HF diagnosed with New York Heart Association (NYHA) Class II-IV at the time of screening.
Exclusion: Currently receiving or anticipated to receive therapeutic intervention for diabetic retinopathy and/or macular edema; more than 1 episode of severe hypoglycemic event within 180 days prior to screening, or hypoglycemia unawareness/poor recognition; Major cardiac surgery, coronary revascularization, valvular repair/replacement, AF/AFL ablation, CRT implantation, or ICD without CRT within 90 days prior to screening, or planned after randomization; Clinically significant upper GI condition affecting gastric emptying, drug absorption, or safety/tolerability interpretation; chronic use of drugs directly affecting GI motility; severe disease or prior surgery; Diabetes exclusions:; History of type 1 diabetes; Heart failure due to infiltrative cardiomyopathy, active myocarditis, constrictive pericarditis, cardiac tamponade, genetic hypertrophic cardiomyopathy (including obstructive), or arrhythmogenic right ventricular cardiomyopathy/dysplasia; History of acute or chronic pancreatitis; History/ family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2, or basal calcitonin ≥35 ng/L at screening; HbA1c ≥10% at screening; On a prespecified renal replacement therapy, or eGFR below a prespecified threshold at screening; BMI <25 kg/m² at screening; Renal exclusions:; Cardiovascular exclusions:; GI exclusions:; Endocrine exclusions:.